Opioid & Fentanyl Addiction Treatment in Southern California

By SoCal Addiction Centers Editorial Team | Last reviewed: | 8 min read Clinically Reviewed

Key Takeaways

  • Fentanyl was involved in more than 70% of California’s overdose deaths in 2023, per the CDPH Overdose Surveillance Dashboard. LA County alone recorded over 2,200 fentanyl-involved deaths.
  • Three FDA-approved medications treat opioid-use disorder (OUD): buprenorphine (Suboxone, Subutex, Sublocade), methadone, and naltrexone (Vivitrol). All three are covered by Medi-Cal DMC-ODS and by commercial plans under state and federal parity law.
  • Methadone is dispensed only at DEA-registered Opioid Treatment Programs (OTPs). SoCal has 6 CARF-accredited flagship OTPs, including the Acadia Comprehensive Treatment Center chain in Wilmington, Murrieta, San Diego, El Cajon, and San Marcos, plus BHS Respite & Recovery Center at MLK Campus in LA.
  • Buprenorphine has no OTP requirement — any licensed prescriber can now prescribe it following the 2022 removal of the X-waiver. Office-based and telehealth OUD treatment has expanded significantly.
  • Naloxone (Narcan) is available without a prescription at California pharmacies under statewide standing order. Family members of OUD patients should have it on hand; the NEXT Distro network provides mail-order Narcan at no cost.
  • Harm reduction is the baseline, not an alternative to treatment. Fentanyl test strips, Narcan, and supervised OUD medication are complementary to behavioral treatment, not substitutes for it.

Opioid addiction in Southern California — the current data

California recorded 7,839 fentanyl-involved overdose deaths in 2023, per the CDPH Overdose Surveillance Dashboard — the most recent full year published at review. Fentanyl was involved in 71% of all overdose mortality statewide. Los Angeles County recorded 2,220 fentanyl-involved deaths that year, the highest raw county count in the United States. Orange, San Diego, Riverside, San Bernardino, and Ventura counties collectively recorded over 1,800 additional fentanyl-involved deaths in the same period.

This page is written for people with opioid-use disorder (OUD) and for families trying to understand the treatment landscape. Every medication named below is FDA-approved. Every facility named has been cross-referenced against the DHCS Licensing and Certification public dataset and CARF provider search. We do not accept referral fees from any facility mentioned.

Fentanyl has changed what opioid treatment looks like

Fentanyl is 50–100 times more potent than morphine. Its arrival in the California supply has changed three things about OUD treatment at a clinical level:

Withdrawal is more severe. Fentanyl-tolerant patients often require higher induction doses of buprenorphine or methadone than patients whose tolerance was built on heroin or prescription opioids. Some patients experience precipitated withdrawal when starting buprenorphine on the older 12–24-hour protocol. Microdosing and “low-dose” buprenorphine induction protocols have been developed specifically for fentanyl-tolerant patients.

Overdose risk is higher at every point of contact. A patient relapsing after detox who has lost tolerance faces a meaningfully higher risk of fatal overdose than a decade ago. This is why every OUD treatment program should co-prescribe naloxone and why starting MAT before residential discharge (rather than after) is clinically preferred.

The “clean” supply is compromised. Counterfeit pressed pills (fake Percocet, fake Xanax, fake Adderall) are routinely found to contain fentanyl. Patients with no intent to use opioids are overdosing on contaminated stimulants or benzodiazepines. Fentanyl test strips are now standard harm-reduction equipment.

Clinicians in SoCal should be calibrated to this landscape. When evaluating a facility’s clinical protocol, ask explicitly: “How do you handle fentanyl-tolerant patients during induction? What is your microdosing capability?” A facility that can’t answer in clinical terms is operating on pre-fentanyl-era protocols.

FDA-approved medications for opioid-use disorder

Three medications are FDA-approved for the treatment of OUD. They are not interchangeable; clinical choice depends on the patient’s medical history, opioid-use pattern, and treatment setting.

Buprenorphine (Suboxone, Subutex, Sublocade)

Buprenorphine is a partial mu-opioid agonist. It binds the opioid receptor strongly enough to prevent withdrawal and reduce cravings, but its ceiling effect limits respiratory depression risk, making it substantially safer in overdose than full agonists. Available as:

  • Sublingual film or tablet (Suboxone = buprenorphine + naloxone; Subutex = buprenorphine alone). Daily dosing. Most common induction and maintenance form.
  • Monthly extended-release injection (Sublocade). Once-monthly subcutaneous injection, administered in office. Removes daily dosing burden.
  • Six-month implant (Probuphine). Rarely used; mostly replaced by Sublocade.

As of 2023, the federal X-waiver requirement for buprenorphine prescribing is eliminated — any DEA-registered practitioner can now prescribe it. In California, this means primary care physicians, psychiatrists, NPs, and PAs can all initiate buprenorphine treatment. Telehealth buprenorphine treatment is fully legal in California.

Methadone

Methadone is a full mu-opioid agonist used for OUD maintenance (and sometimes for pain, under different regulatory rules). Federal law restricts methadone for OUD to dispensing at DEA-registered Opioid Treatment Programs (OTPs). Patients receive daily observed dosing initially, transitioning to take-home doses over months as clinical stability is established.

SoCal’s CARF-accredited flagship OTPs include:

  • Coastal Comprehensive Treatment Center (Wilmington, LA County) — Acadia Healthcare
  • Temecula Valley Comprehensive Treatment Center (Murrieta, Riverside County)
  • Fashion Valley Comprehensive Treatment Center (San Diego)
  • El Cajon Comprehensive Treatment Center (El Cajon, San Diego County)
  • Capalina Comprehensive Treatment Center (San Marcos, San Diego County)
  • BHS Respite & Recovery Center at MLK Campus (Los Angeles)

Additional DHCS-licensed OTPs operate across the six SoCal counties at our verified and listed tiers. The SAMHSA Behavioral Health Treatment Services Locator filters OTPs specifically.

Naltrexone (Vivitrol)

Naltrexone is a mu-opioid antagonist — it blocks the opioid receptor entirely. Patients must be opioid-free for 7–10 days before starting, making it a post-detox maintenance medication rather than an induction option. Available as:

  • Oral tablet — daily dosing. Adherence challenges limit effectiveness in OUD.
  • Monthly extended-release injection (Vivitrol) — once-monthly intramuscular injection. Removes adherence issues.

Naltrexone also has an FDA indication for alcohol-use disorder, which is discussed in our alcohol addiction pillar.

Levels of care for opioid-use disorder

Opioid-use disorder can be treated at any ASAM level of care, from outpatient office-based buprenorphine prescribing to medically monitored residential treatment. The appropriate level depends on withdrawal severity, medical complexity, psychiatric comorbidity, and social circumstances.

Outpatient (ASAM Level 1.0) — Office-based buprenorphine prescribing. Appropriate for many stable OUD patients with social support, stable housing, and no significant medical or psychiatric complications. Usually combined with weekly or bi-weekly counseling.

Intensive Outpatient (ASAM Level 2.1) — 9+ hours of structured treatment per week. Appropriate for moderate complexity or as a step-down from residential. Most CARF-accredited SoCal IOP programs accept OUD patients on MAT.

Partial Hospitalization (ASAM Level 2.5) — 20+ hours per week. Appropriate for patients who need more intensity than IOP but can safely live at home.

Residential (ASAM Levels 3.1, 3.3, 3.5, 3.7) — 24-hour care in a non-hospital setting. MAT is continued throughout residential; any program that requires patients to discontinue buprenorphine or methadone to enter is operating against current ASAM and SAMHSA clinical guidance. Our inpatient & residential rehab pillar details the residential levels.

Hospital-based detox (ASAM Level 4.0-WM) — For severe withdrawal with medical complications. Rarely needed for opioid withdrawal alone (which is not typically fatal), but indicated for complex polysubstance cases.

The clinical standard in 2026: MAT is first-line treatment for OUD at every level of care. A facility requiring patients to taper off buprenorphine or methadone to “graduate” is not practicing evidence-based medicine.

Naloxone (Narcan) access in California

Naloxone — brand name Narcan — is an opioid antagonist that rapidly reverses opioid overdose. Intranasal Narcan is available without a prescription at every California pharmacy under AB 1535 and subsequent statewide standing order.

How to get Narcan in SoCal:

  • Any pharmacy (CVS, Walgreens, Rite Aid, Costco, and county-contracted pharmacies) under statewide standing order
  • NEXT Distro — mail-order at no cost, nationwide
  • LA County DPH Substance Abuse Prevention and Control — free distribution events and community access points, schedule at publichealth.lacounty.gov/sapc/
  • Many community syringe-services programs and harm-reduction organizations

Family members, friends, and anyone in regular contact with an OUD patient should have Narcan. Carrying and using it does not create legal liability under California’s Good Samaritan laws.

Treatment coverage for opioid-use disorder

OUD treatment — including all three FDA-approved medications — is covered by:

  • Medi-Cal DMC-ODS — Full coverage, zero out-of-pocket, at contracted providers in all 6 SoCal counties. See our Medi-Cal coverage pillar.
  • Medicare — Part B covers office-based buprenorphine, methadone OTPs (as of 2020), counseling, and office visits. Part A covers inpatient detox and hospital-based treatment.
  • Commercial insurance — All California-regulated plans cover MAT under state and federal parity law.
  • Tricare — Covers MAT for eligible military beneficiaries.

Facilities that refuse to accept patients on MAT — or that require patients to discontinue MAT as a condition of admission — are not practicing evidence-based medicine and are also potentially running afoul of ADA protections. The Department of Justice has enforced this in several cases involving residential facilities and sober living operators.

Need help finding MAT in Southern California?

Our editorial team can help you identify buprenorphine, methadone, or naltrexone access in your county, insurance network, and at the clinical level of care you need. We do not accept referral fees. Calls are informational.

Contact our editorial team →

Use the Verify Insurance tool →

Need help now? Call (310) 596-1751 for editorial guidance. For immediate overdose crisis, call 911. For non-emergency crisis support, dial 988.

Last reviewed: 2026-04-23. Overdose statistics reflect CDPH Overdose Surveillance Dashboard data current at review. Medication information reflects current FDA labeling and SAMHSA/ASAM clinical guidance. This page is editorial content, not medical advice. For specific clinical decisions, consult a licensed addiction medicine physician.

Looking for treatment options in your area? We can help point you in the right direction. (310) 596-1751 — or request a callback.